Survey reveals less than half of Americans plan to get flu shot this season


A survey conducted by the National Foundation for Infectious Diseases (NFID) revealed that only 49 percent of polled U.S. adults plan to get a flu shot this season, CNBC reports.
The data shows that 1 in 5 respondents at higher risk for influenza-related complications reported that they do not plan to get the annual vaccine this season. People over 65 years old, pregnant people, patients with underlying conditions, and children under five face a significant risk of severe outcomes if infected with the flu, per the Centers for Disease Control and Prevention.
The NFID survey found that while nearly 70 percent of people agreed that the annual flu shot was the best way to prevent fatal influenza infections, many are still electing not to get the vaccine this year. CNBC reports that 58 percent of the Americans surveyed plan to wear masks at least part of the time to protect themselves during flu season, which exceeds the number who plan to get the shot.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Per the NFID survey, some of the top reasons for not getting the vaccine include believing that the flu shot is ineffective and concerns over potential side effects.
"With COVID, people have forgotten about influenza," said William Schaffner, medical director of NFID, at an NFID conference on Tuesday. "This is another serious winter respiratory virus, it can do bad damage to you. The key to prevention is vaccination."
The survey polled 1,005 adult respondents throughout the United States and was conducted via phone and web between Aug. 11 and 15. The overall margin of error is +/- 4.2 percentage points.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Theara Coleman has worked as a staff writer at The Week since September 2022. She frequently writes about technology, education, literature and general news. She was previously a contributing writer and assistant editor at Honeysuckle Magazine, where she covered racial politics and cannabis industry news.
-
Can TrumpRx really lower drug prices?
Today’s Big Question Pfizer’s deal with Trump sent drugmaker stocks higher
-
FDA OKs generic abortion pill, riling the right
Speed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
‘Nightmare bacteria’ are rapidly spreading
Under the radar The infections are largely resistant to antibiotics
-
Private equity firms might be causing more deaths in hospital ERs
The Explainer Deaths in ERs purchased by private equity firms rose 13%
-
Why are autism rates increasing?
The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shot
Speed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Quit-smoking ads are being put out
Under the radar The dissolution of a government-funded campaign could lead to more smokers in the future
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada